Cancer Supportive Care

Cancer
supportive care

The cancer supportive care products market, estimated to be worth $13.8 billion in 2006, is growing rapidly due to the:

Increasing burden of cancer among the ageing population

Greater effectiveness of anti-cancer treatments, making cancer a 'chronic' disease.

Increased focus on the importance of quality of life

Introduction of novel targeted anti-cancer agents with specific side-effect profiles that provide new challenges to physicians/carers in terms of patient management

Ondansetron
ODF

Nausea
and vomiting

Patients worldwide have increasing needs for treatment of nausea and vomiting, especially as part of cancer therapy. A recent market report forecasts the world market for antiemetic drugs will reach $4.6 billion in 2018, rising further to 2024 due to the global rise in cancer levels - cancer treatment is the leading cause of nausea and vomiting.

To encourage treatment compliance, drug companies are developing antiemetic therapies with novel delivery methods.

Oncodermatology

Oncodermatology (dermatologic adverse events due to cancer therapy) investigations show that 40-90% of patients taking targeted oncological therapies experience skin toxicities, costing an average of $2000/patient.

Oncodermatological side-effects can lead to interruption of treatment, thereby reducing efficacy and incurring extra costs.